3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Adenoviridae Infections
1
Interventions
valrubicin
2
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma in Situ
×
valrubicin
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled
NCT01316874
2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3
Completed
90 enrolled